

Reaction of Spiro[2.4]hepta-4,6-diene with Molybdenum(II) Indenyl **Compounds: Effects of Substitution in the Indenyl Ligand**

Jan Honzíček,^{*,†,‡} Carlos C. Romão,^{*,†} Maria J. Calhorda,[§] Abhik Mukhopadhyay,[∥] Jaromír Vinklárek,[‡] and Zdeňka Padělková[‡]

[†]Instituto de Tecnologia Química e Biológica da Universidade Nova de Lisboa, Av. da República, EAN, 2780-157, Oeiras, Portugal, ${}^{\ddagger} \widetilde{D}$ epartment of \widetilde{G} eneral and Inorganic Chemistry, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic, [§]Departamento de Química e Bioquímica, CQB, Faculdade de Ciências da Universidade de Lisboa, 1749-016 Lisboa, Portugal, and REQUIMTE/CQFB, Departamento de Química, FCT-UNL, 2829-516 Monte de Caparica, Portugal

Received August 30, 2010

The series of molybdenum indenyl compounds [(Ind')Mo(CO)₂(NCMe)₂][BF₄] was prepared, and their reactivity toward spiro[2.4]hepta-4,6-diene was studied. It was observed that the spiro-[2.4]hepta-4,6-diene ring opening could be blocked through substitution in the indenvl ring. Hence, the 2-substituted compound $[(\eta^5-C_9H_6Me)Mo(CO)_2(NCMe)_2][BF_4]$ and 1,3-disubstituted compound $[(\eta^5 - C_9 H_5^t Bu_2) Mo(CO)_2(NCMe)_2][BF_4]$ do not produce the usual ansa-compounds but the compounds with η^4 -bonded spiro[2.4]hepta-4,6-diene [(Ind')(η^4 -C₅H₄(CH₂)₂)Mo(CO)₂][BF₄]. The use of 1-substituted compounds $[(\eta^5 - C_9H_6R)Mo(CO)_2(NCMe)_2][BF_4](R = Ph, ^tBu)$ or compounds with less sterically demanding substituents in the 1,3-positions $[(\eta^5-C_9H_5Ph_2)Mo(CO)_2(NCMe)_2]$ [BF₄] does not block the ring-opening reaction. These compounds give ansa-molybdenocenes $[(Ind')(\eta^5-C_5H_4CH_2-\eta^1-CH_2)Mo(CO)][BF_4]$ in a manner similar to that for the unsubstituted analogue. The reaction products were characterized by NMR and IR spectroscopy. Structures of $[(\eta^5 - C_9H_5Ph_2)Mo(\eta^3 - C_3H_5)(CO)_2], [(\eta^5 - C_9H_6Ph)(\eta^5 - C_5H_4CH_2 - \eta^1 - CH_2)Mo(CO)][BF_4], and [(\eta^5 - C_9H_6Ph)(\eta^5 - C_5H_4CH_2 - \eta^1 - CH_2)Mo(CO)][BF_4], and [(\eta^5 - C_9H_6Ph)(\eta^5 - C_5H_4CH_2 - \eta^1 - CH_2)Mo(CO)][BF_4], and [(\eta^5 - C_9H_6Ph)(\eta^5 - C_5H_4CH_2 - \eta^1 - CH_2)Mo(CO)][BF_4], and [(\eta^5 - C_9H_6Ph)(\eta^5 - C_5H_4CH_2 - \eta^1 - CH_2)Mo(CO)][BF_4], and [(\eta^5 - C_9H_6Ph)(\eta^5 - C_9H_6Ph)$ $C_9H_5Ph_2)(\eta^5-C_5H_4CH_2-\eta^1-CH_2)MO(CO)][BF_4]$ were determined by single-crystal X-ray analysis.

Introduction

Molybdenocene dichloride (Cp2MoCl2) has received great attention, due to its antitumor¹ and catalytic activity.² Aqueous solutions of molybdenocene compounds catalyze various processes, including H/D exchange through C-H activation,³ transfer hydrogenation,⁴ nitrile hydration,⁵ and hydrolysis of carboxylic acid esters,⁵ phosphate esters,^{5,6}

- Naturforsch., C 1979, 34, 1174-1176. (b) Abeysinghe, P. M.; Harding, M. M. Dalton Trans. 2007, 3474-3482. (c) Waern, J. B.; Harding, M. M. J. Organomet. Chem. 2004, 689, 4655-4668.
- (2) Breno, K. L.; Ahmed, T. J.; Pluth, M. D.; Balzarek, C.; Tyler,
 D. R. Coord. Chem. Rev. 2006, 250, 1141–1151.
- (3) (a) Balzarek, C.; Tyler, D. R. Angew. Chem., Int. Ed. 1999, 38, 2406–2408. (b) Balzarek, C.; Weakley, T. J. R.; Tyler, D. R. J. Am. Chem. Soc. 2000, 122, 9427–9434.
- (4) Kuo, L. Y.; Finigan, D. M.; Tadros, N. N. Organometallics 2003, 22, 2422–2425.
- (5) Ahmed, T. J.; Zakharov, L. N.; Tyler, D. R. Organometallics 2007, 26, 5179-5187.
 - (6) Kuo, L. Y.; Barnes, L. A. Inorg. Chem. 1999, 38, 814-817.
- (7) (a) Kuo, L. Y.; Blum, A. P.; Sabat, M. Inorg. Chem. 2005, 44, (a) Rub, E. T., Bhin, A. T., Sabat, M. *mog. Chem.* 2005, 77, 5537–5541. (b) Kuo, L. Y.; Adint, T. T.; Akagi, A. E.; Zakharov, L. *Organometallics* 2008, *27*, 2560–2564.
 (8) Honziček, J.; Paz, F. A. A.; Romão, C. C. *Eur. J. Inorg. Chem.*
- 2007, 2827-2838.
- (9) Honzíček, J.; Mukhopadhyay, A.; Silva, T. S.; Romão, M. J.; Romão, C. C. Organometallics 2009, 28, 2871-2879.

Scheme 1. Reaction of $[Cp'Mo(CO)_2(NCMe)_2][BF_4]$ (1, Cp' =Cp; 2, Cp' = Ind) with Spiro[2.4]hepta-4.6-diene



and thiophosphinates.7 A part of our research on molybdenocenes^{8,9} involves the quest for new ring-substituted compounds with improved biological and catalytic properties.¹⁰

One of the specific synthetic routes giving molybdenum cyclopentadienyl complexes uses C-C activation of 5,5'disubstituted cyclopentadienes with molybdenum metal or carbonyls. The transfer of the alkyl group is accompanied by aromatization of the cyclopentadienyl ring and oxidation of the metal center.^{11,12} This method was found to be suitable

^{*}To whom correspondence should be addressed. E-mail: jan. honzicek@upce.cz (J.H.); ccr@itqb.unl.pt (C.C.R.). Fax: +420/46603 7068 (J.H.); +351-21-441 12 77 (C.C.R.). (1) (a) Köpf-Maier, P.; Leitner, M.; Voigtlander, R.; Köpf, H. Z.

⁽¹⁰⁾ Ahmed, T. J.; Tyler, D. R. Organometallics 2008, 27, 2608-2613.

⁽¹¹⁾ Green, J. C.; Green, M. L. H.; Morley, C. P. J. Organomet. Chem. 1982, 233, C4-C6.

⁽¹²⁾ King, R. B.; Efraty, A. J. Am. Chem. Soc. 1971, 93, 4950-4952.

Scheme 2. Synthesis of the Ring-Substituted Indenyl Complexes [(Ind')Mo(CO)₂(NCMe)₂][BF₄] (10-14)



for synthesis of some Cp* (C₅Me₅⁻) metal complexes when C₅Me₆ or C₅Me₅COOMe is used.^{11,13} However, most of the attention has been given to reactions with spirocyclic cyclopentadienes which produce *ansa*-compounds that are suitable precursors for a variety of ring-functionalized compounds.^{14,15} In our laboratory, the reactivity of spiro[2.4]hepta-4,6-diene toward the cationic molybdenum complexes [Cp'Mo(CO)₂-(NCMe)₂][BF₄] (**1**, Cp' = Cp; **2**, Cp' = Ind) was investigated.⁸ It was observed that the cyclopentadienyl compound [CpMo(CO)₂(NCMe)₂][BF₄] (**1**) gives the stable η^4 -diene complex [Cp(η^4 -C₅H₄(CH₂)₂)Mo(CO)₂[BF₄] (**3**), while the indenyl analogue [IndMo(CO)₂(NCMe)₂][BF₄] (**2**) produces the ring-opening product [Ind(η^5 -C₅H₄CH₂- η^1 -CH₂)Mo(CO)][BF₄] (**4**) in high yield (see Scheme 1).

A theoretical investigation of these reactions has shown that the discrepancy in the reactivity is a result of activation through $\eta^5 - \eta^3$ ring slippage that is favorable in the case of indenyl compounds.¹⁶ However, this haptotropic reactivity enhancement is kinetically controlled and requires a rather subtle, nonobvious series of structural rearrangements of the coordination sphere prior to ring opening. Since such rearrangements are likely to respond to the presence of substituents on the indenyl ring, the present study of the reactivity of spiro[2.4]hepta-4,6-diene with ring-substituted indenyl complexes [(Ind')Mo(CO)₂(NCMe)₂][BF₄] was designed to provide a more detailed insight into the mechanism of the spiro[2.4]hepta-4,6-diene ring-opening reaction.

Results

Synthesis of Ring-Substituted Indenyl Complexes. The cationic indenyl complexes $[(Ind')Mo(CO)_2(NCMe)_2][BF_4]$ (10–14) were prepared from $[(\eta^3-C_3H_5)Mo(CO)_2(NCMe)_2X]$ (X = Cl, Br) and the lithium salt of the appropriate indene using the route developed for the unsubstituted analogue 2 (Scheme 2).^{17,18}



Figure 1. ORTEP drawing of $[(\eta^5-C_9H_5Ph_2)Mo(\eta^3-C_3H_5)-(CO)_2]$ (8). The labeling scheme for all non-hydrogen atoms is shown. Thermal ellipsoids are drawn at the 30% probability level. Hydrogen atoms of the η^3 -allyl group have been omitted for clarity. Selected bond lengths (Å) and bond angles (deg): Mo1-C1 = 1.955(3), Mo1-C2 = 1.943(3), Mo1-C6 = 2.373(2), Mo1-C7 = 2.300(2), Mo1-C8 = 2.326(2), Mo1-C9 = 2.414(2), Mo1-C10 = 2.446(2), Mo1-Cg(C6-C10) = 2.0341(10), C1-O1 = 1.155(3), C2-O2 = 1.152(3); C1-Mo1-C2 = 80.57(10), Mo1-C2-O2 = 179.3(2), Mo1-C1-O1 = 178.1(2).

The allyl intermediates $[(Ind')Mo(\eta^3-C_3H_5)(CO)_2]$ (5, 6, 8, and 9) were isolated and characterized by spectroscopic methods. Infrared spectra of these compounds show two bands in the region of CO stretching at ~1940 and 1860 cm⁻¹. Compounds 5, 6, 8, and 9 form mixtures of *exo* and *endo* isomers in solution, as was evidenced by NMR spectroscopy. At room temperature, the molar ratios between *exo* and *endo* isomers were found to be 4:1 for 5, 3:1 for 6, 3.4:1 for 8, and 3:1 for 9. The structure of compound 8 was determined by X-ray analysis (Figure 1).

Protonation of $[(Ind')Mo(\eta^3-C_3H_5)(CO)_2]$ (5–9) with HBF₄ in the presence of acetonitrile gives the cationic complexes $[(Ind')Mo(CO)_2(NCMe)_2][BF_4]$ (10–14). NMR measurements prove the coordination of two MeCN ligands and the presence of the η^5 -coordinated substituted indenyl ring. The infrared spectra show two bands in the region of terminal carbonyls at ~1960 (vs) and ~1870 cm⁻¹ (vs) and two bands of the cyano groups at ~2310 (m) and ~2280 cm⁻¹ (m). The broad band of the B–F stretching at ~1055 cm⁻¹ proves the presence of the BF₄ anion. 1,3-Di-*tert*-butylindene, necessary for the synthesis of **6**, was prepared using the fulvene protocol (see Scheme 3). Condensation of 3-*tert*-butylindene with acetone in the presence of KOH gives 3-*tert*-butyl-1-isopropylideneindene. Subsequent reaction

⁽¹³⁾ King, R. B.; Efraty, A. J. Am. Chem. Soc. 1972, 94, 3773–3779.
(14) (a) Raith, A.; Altmann, P.; Cokoja, M.; Herrmann, W. A.;
Kühn, F. E. Coord. Chem. Rev. 2010, 254, 608–634. (b) Capapé, A.;
Raith, A.; Herdtweck, E.; Cokoja, M.; Kühn, F. E. Adv. Synth. Catal. 2010, 352, 547–556. (c) Capapé, A.; Raith, A.; Kühn, F. E. Adv. Synth. Catal. 2009, 351, 66–70. (d) Zhao, J.; Jain, K. R.; Herdtweck, E.; Kühn, F. E. Dalton Trans. 2007, 5567–5571. (e) Zhao, J.; Herdtweck, E.; Kühn, F. E. J. Organomet. Chem. 2006, 691, 2199–2206. (f) Moriarty, R. M.; Chen, K. M.; Churchill, M. R.; Chang, S. W. Y. J. Am. Chem. Soc. 1974, 96, 3661–3663. (g) Eilbracht, P. Chem. Ber 1976, 109, 1429–1435. (h) Eilbracht, P. Chem. Ber.-Recl. 1976, 109, 3136–3141. (i) Eilbracht, P.; Dahler, P. J. Organomet. Chem. 1977, 127, C48–C50. (j) Barretta, A.; Chong, K. S.; Cloke, F. G. N.; Feigenbaum, A.; Green, M. L. H. J. Chem. Soc., Dalton Trans. 1983, 861–864. (k) Green, M. L. H.; Ohare, D. J. Chem. Soc., Dalton Trans. 1982, 1, 1586–1590. (l)

⁽¹⁵⁾ Amor, F.; Royo, P.; Spaniol, T. P.; Okuda, J. J. Organomet. Chem. 2000, 604, 126-131.

⁽¹⁶⁾ Veiros, L. F.; Honzíček, J.; Romão, C. C.; Calhorda, M. J. Inorg. Chim. Acta 2010, 363, 555–561.

⁽¹⁷⁾ Faller, J. W.; Chen, C. C.; Mattina, M. J.; Jakubowski, A. J. Organomet. Chem. **1973**, *52*, 361–386.

 ⁽¹⁸⁾ Ascenso, J. R.; de Azevedo, C. G.; Gonçalves, I. S.; Herdtweck,
 E.; Moreno, D. S.; Pessanha, M.; Romão, C. C. *Organometallics* 1995,
 14, 3901–3919.



Scheme 4. Reaction of Compounds 10 and 11 with Spiro[2.4]hepta-4,6-diene



with an excess of MeLi followed by hydrolysis produces the 1,3-di-*tert*-butylindene in 14% overall yield. An alternative pathway giving 1,3-di-*tert*-butylindene uses the reaction of *tert*-butyl chloride with the lithium salt of 3-*tert*-butylindene. Use of this route is limited by very low yields ($\sim 3\%$). Other substituted indenes were prepared according to literature procedures.^{19–22}

Reaction of $[(Ind')Mo(CO)_2(NCMe)_2][BF_4]$ (10–14) with Spiro[2.4]hepta-4,6-diene. The replacement of MeCN ligands by spiro[2.4]hepta-4,6-diene leads in most cases to the opening of the cyclopropyl ring and oxidative addition of a C–C bond to the Mo atom, as shown in the examples of Scheme 4. The absence of a plane of symmetry in the 1-substituted indenyl complexes [(Ind')Mo(CO)_2(NCMe)_2][BF_4] may result in the appearance of two diastereoisomeric products (a and b) of the ring-opening reaction. However, in practice, a good degree of selectivity is seen in the reaction of spiro-[2.4]hepta-4,6-diene with the *tert*-butylindenyl compound 10 and the phenyl-substituted compound 11.

Compound **15a** was found to be the sole product of the reaction between **10** and spiro[2.4]hepta-4,6-diene. The phenyl-substituted analogue **11** gives both possible products (**16a**,**b**). The experiments in CD₂Cl₂ followed by NMR spectroscopy have shown that **16a**,**b** appear in the molar ratio 30:1. Multiple recrystallizations from a CH₂Cl₂-hexane mixture give pure isomer **16a**.

The diastereoisomers **a** and **b** were distinguished on the basis of ¹H NMR measurements. The methylene proton H^B from the group connected to molybdenum was found to be suitable for this purpose (Scheme 1). Due to the shielding effect of the benzene ring, the indenyl compound [(Ind)(η^{5} -C₅H₄CH₂- η^{1} -CH₂)Mo(CO)][BF₄] (4) shows the signal for

Table 1. Chemical Shifts (ppm) of the CH₂Mo Moiety in ¹H NMR Spectra of the *ansa*-Compounds $[(Cp')Mo(\eta^5-C_5H_4CH_2-\eta^1-CH_2)(CO)][BF_4]$

Cp′	H^{A}	H^B	ref		
η^5 -C ₅ H ₅	-0.41	-0.89	8		
η^{5} -C ₉ H ₇ (4)	-0.07	-3.21	8		
η^{5} -C ₉ H ₆ ^{<i>t</i>} Bu (15a)	-0.70	-3.05			
η^{5} -C ₉ H ₆ Ph (16a)	-0.09	-3.75			
η_{2}^{5} -C ₉ H ₆ Ph (16b)	-0.49	-1.63			
η^{2} -C ₉ H ₅ Ph ₂ (18)	-0.32	-2.50			

H^B at much higher field than for its cyclopentadienyl analogue [(Cp)(η^{5} -C₅H₄CH₂- η^{1} -CH₂)Mo(CO)][BF₄] (3); see Table 1. A similar effect was observed for isomers a and **b**. The compounds 15a and 16a show the shift of H^B close to the value observed for the indenvl compound 4, while the shift in compound 16b was found to be similar to that of the cyclopentadienyl compound 3. These differences were assigned to the shielding effect of the benzene. The steric effects cause the monosubstituted compounds to prefer the conformation with the bulky substituent in the position above the OC-Mo-CH₂ moiety (see Scheme 4). In this conformation, isomer a has the benzene ring of the indenyl on the side of the CH₂ group, while isomer **b** has it on the side of the carbonyl ligand. This behavior causes the isomers a to exhibit a much stronger effect of the benzene ring than the isomer **b**.

The molecular structure of the compound **16a** obtained from X-ray diffraction analysis (see Figure 2) supports the NMR spectra assignment.

The η^4 -diene complex $[(\eta^5-C_9H_5^tBu_2)(\eta^4-C_5H_4(CH_2)_2)-Mo(CO)_2][BF_4]$ (17) is formed upon reaction of the 1,3-ditert-butyl compound $[(\eta^5-C_9H_5^tBu_2)Mo(CO)_2(NCMe)_2]-$ [BF₄] (12) with spiro[2.4]hepta-4,6-diene (Scheme 5).

The product is stable at room temperature. The reaction of the 1,3-diphenyl analogue **13** gives the *ansa*-compounds $[(\eta^5-C_9H_5Ph_2)(\eta^5-C_5H_4CH_2-\eta^1-CH_2)Mo(CO)][BF_4]$ (**18**) under the same conditions.

Compounds 17 and 18 were characterized by spectroscopic methods. The ¹H NMR spectrum of 17 shows two triplets of the cyclopentadiene protons at 5.54 and 4.19 ppm $({}^{3}J({}^{1}\text{H},{}^{1}\text{H}) = 2.9 \text{ Hz})$ and two triplets of the methylene groups at 1.36 and 0.67 ppm $({}^{3}J({}^{1}\text{H},{}^{1}\text{H}) = 8.6 \text{ Hz})$. This pattern is typical for η^{4} -spiro[2.4]hepta-4,6-diene. The *ansa*compounds 18 shows four multiplets of the methylene protons at 2.62, 2.34, -0.32, and -2.50 ppm. The signals of the methylene carbons were found at 18.8 and -36.7 ppm. The presence of only one carbonyl group in compound 18 is evident from the infrared spectrum. It shows only one band in the CO stretching region at 2006 cm⁻¹. The molecular structure of compound 18 was determined by X-ray diffraction analysis (see Figure 3).

The compound $[(\eta^5-C_9H_6Me)Mo(CO)_2(NCMe)_2][BF_4]$ (14) reacts with spiro[2.4]hepta-4,6-diene, giving the η^4 -diene complex $[(\eta^5-C_9H_6Me)(\eta^4-C_5H_4(CH_2)_2)Mo(CO)_2][BF_4]$ (19) (Scheme 6).

The coordinated spiro[2.4]hepta-4,6-diene gives two triplets of cyclopentadiene at 5.28 and 4.70 ppm $({}^{3}J({}^{1}H,{}^{1}H) = 2.9 \text{ Hz})$ and two triplets of the methylene groups at 1.16 and 0.52 ppm $({}^{3}J({}^{1}H,{}^{1}H) = 8.4 \text{ Hz})$. These values are similar to those observed for the cyclopentadienyl and 1,3-di-*tert*-buty-lindenyl analogues $[(\eta^{5}-C_{5}H_{5})(\eta^{4}-C_{5}H_{4}(CH_{2})_{2})Mo(CO)_{2}]$ -[BF₄] (3)⁸ and $[(\eta^{5}-C_{9}H_{5}{}^{t}Bu_{2})(\eta^{4}-C_{5}H_{4}(CH_{2})_{2})Mo(CO)_{2}]$ -[BF₄] (17), respectively.

⁽¹⁹⁾ Ready, T. E.; Chien, J. C. W.; Rausch, M. D. J. Organomet. Chem. 1996, 519, 21-28.

⁽²⁰⁾ Mills, N. S.; Llagostera, K. B.; Tirla, C.; Gordon, S. M.; Carpenetti, D. J. Org. Chem. **2006**, *71*, 7940–7946.

⁽²¹⁾ Bordwell, F. G.; Drucker, G. É. J. Org. Chem. **1980**, 45, 3325–3328.

⁽²²⁾ Schneider, N.; Huttenloch, M. E.; Stehling, U.; Kirsten, R.; Schaper, F.; Brintzinger, H. H. Organometallics **1997**, *16*, 3413–3420.



Figure 2. ORTEP drawing of the two crystallographically independent molecules of $[(\eta^5-C_9H_6Ph)(\eta^5-C_5H_4CH_2-\eta^1-CH_2)Mo(CO)]^+$ present in the crystal structure of **16a** (*S* and *R* configurations). The labeling scheme for all non-hydrogen atoms is shown. Thermal ellipsoids are drawn at the 30% probability level. Selected bond lengths (Å) and bond angles (deg): Mo1-C23 = 1.990(3), Mo1-C7 = 2.280(3), Mo1-Cg(C1-C5) = 1.9501(13), Mo1-Cg(C8-C16) = 2.0152(13), Mo1-C1 = 2.294(3), Mo1-C2 = 2.286(3), Mo1-C3 = 2.290(3), Mo1-C4 = 2.307(3), Mo1-C5 = 2.292(3), Mo1-C8 = 2.369(3), Mo1-C13 = 2.476(3), Mo1-C14 = 2.373(3), Mo1-C15 = 2.288(3), Mo1-C16 = 2.264(3), C23-O1 = 1.138(4), Mo2-C46 = 2.001(3), Mo2-C30 = 2.286(3), Mo2-Cg-(C24-C28) = 1.9457(13), Mo2-Cg(C31-C35) = 2.0152(13), Mo2-C24 = 2.287(3), Mo2-C25 = 2.284(3), Mo2-C26 = 2.287(3), Mo2-C27 = 2.289(3), Mo2-C28 = 2.306(3), Mo2-C31 = 2.382(3), Mo2-C32 = 2.276(3), Mo2-C33 = 2.282(3), Mo2-C34 = 2.332(3), Mo2-C35 = 2.464(3), C46-O2 = 1.136(4); C7-Mo1-C23 = 91.29(12), Cg(C1-C5)-Mo1-Cg(C8-C16) = 145.27(6), Mo1-C7-C6 = 101.43(18), Mo1-C23-O1 = 177.3(3), C30-Mo2-C46 = 89.42(13), Cg(C24-C28)-Mo2-Cg(C31-C35) = 144.81(6), Mo2-C28-C29 = 101.49(19), Mo2-C46-O2 = 176.7(3).

Scheme 5. Reaction of 1,3-Disubstituted Compounds 12 and 13 with Spiro[2.4]hepta-4,6-diene



Attempts to observe the intermediates of the reaction between $[(Ind')Mo(CO)_2(NCMe)_2][BF_4]$ (2, 10, 11, and 13) and spiro[2.4]hepta-4,6-diene were unsuccessful. The appropriate *ansa*-compounds appear immediately after mixing the starting compounds in CD_2Cl_2 and running the ¹H NMR spectra as fast as possible.

The compounds with coordinated spiro[2.4]hepta-4,6diene [(Ind')(η^4 -C₅H₄(CH₂)₂)Mo(CO)₂][BF₄] (**17** and **19**) are stable at room temperature. All attempts to force the spiro[2.4]hepta-4,6-diene ring-opening reaction by heating or by irradiating their solutions with a tungsten bulb led to decomposition. None of the expected *ansa*-compounds were obtained. Instead, a mixture of intractable products probably due to the polymerization of spiro[2.4]hepta-4,6-diene was formed.



Figure 3. ORTEP drawing of the cation $[(\eta^5-C_9H_5Ph_2)(\eta^5-C_5H_4CH_2-\eta^1-CH_2)Mo(CO)]^+$ present in the crystal structure of **18**. The labeling scheme for all non-hydrogen atoms is shown. Thermal ellipsoids are drawn at the 30% probability level. Selected bond lengths (Å) and bond angles (deg): Mo1-C1 = 1.999(6), Mo1-C29 = 2.297(6), Mo-Cg(C23-C27) = 1.952(3), Mo-Cg(C2-C10) = 2.009(2), Mo1-C23 = 2.306(6), Mo1-C24 = 2.282(6), Mo1-C25 = 2.290(6), Mo1-C26 = 2.293(6), Mo1-C27 = 2.294(6), Mo1-C2 = 2.305(5), Mo1-C3 = 2.295(5), Mo1-C4 = 2.337(5), Mo1-C5 = 2.439(5), Mo1-C10 = 2.377(5), C1-O1 = 1.126(7); C1-Mo1-C29 = 89.2(3), Cg(C23-C27)-Mo-Cg(C2-C10) = 143.59(12), Mo1-C29-C28 = 101.2(4), Mo1-C1-O1 = 175.2(6).

Crystal Structures. The structure of the allyl complex $[(\eta^5 - C_9H_5Ph_2)Mo(\eta^3 - C_3H_5)(CO)_2]$ (8) and the two *ansa*-compounds $[(Ind')(\eta^5 - C_5H_4CH_2 - \eta^1 - CH_2)Mo(CO)][BF_4]$ (16a, $Ind' = \eta^5 - C_9H_6Ph$; 18, $Ind' = \eta^5 - C_9H_5Ph_2$) were determined

Scheme 6. Reaction of Compound 14 with Spiro[2.4]hepta-4.6-diene



by X-ray diffraction analysis. Their crystallographic data are summarized in Table 2. Compound **16a** has two crystallographically independent complexes in the unit cell that are essentially the same. They are shown in Figure 2.

The molecule of compound **8** has distorted-tetrahedral coordination around Mo(II) with η^3 -allyl, η^5 -bonded substituted indenyl and two carbonyl ligands (Figure 1). The Mo-C(CO) bond lengths are 1.943(3) and 1.955(3) Å. The C(CO)-Mo-C(CO) bond angle was found to be 80.57(10)°. The distance between the molybdenum atom and the centroid of the η^5 -bonded indenyl is 2.0341(10) Å. The Mo-C-(Ind) distances vary between 2.300(2) and 2.446(2) Å. The phenyl groups are not coplanar with the indenyl framework. The interplanar angles between phenyl groups and the five-membered ring of the indenyl group are 39.36(12) and 40.16(13)°.

The cations of compounds 16a and 18 have a bentmetallocene structure with the ligands $\eta^5:\eta^1$ -cyclopentadienidoethyl, η^5 -bonded substituted indenyl, and one carbonyl. They make a distorted tetrahedron around Mo(IV). The angle Cg(Cp)-Mo-Cg(Ind) was found to be 145.27(6)° for 16a(A), 144.81(6)° for 16a(B), and 143.59(12)° for 18. The bond angle $C(CO)-Mo-C(CH_2)$ is 91.29(12)° for 16a(A), 89.42(13)° for 16a(B), and 89.2(3)° for 18. These parameters are similar to those previously obtained for the unsubstituted analogue [(Ind)(η^5 -C₅H₄CH₂- η^1 -CH₂)Mo(CO)][BF₄] (Cg- $(Ind)-Mo-Cg(Cp) = 145.43(2), 145.43(2)^{\circ}; C(CO)-Mo C(CH_2) = 88.5(2), 92.4(2)^\circ$.⁸ The distance between the molybdenum atom and the centroid of the cyclopentadienyl ligand (1.946(1)-1.952(3) Å) and the bond lengths Mo-C(CH₂) (2.280(3)-2.297(6) Å) are in line with those for other molybdenum(IV) compounds containing an η^5 : η^1 -cyclopentadienidoethyl ligand (Mo-Cg(Cp) = 1.934-1.983(4) Å, Mo-C(CH₂) = 2.268(5)-2.281(7) Å).^{8,23} The bond lengths Mo-C(CO) were found to be 1.990(3) Å for 16a(A), 2.001(3) Å for 16a(B), and 1.999(6) Å for 18. The distances between molybdenum and the five-membered ring of indenyl are 2.0152(13) Å for 16a(A), 2.0063(12) Å for 16a(B), and 2.009(2) Å for 18. The phenyl groups are not coplanar with the indenyl framework. The interplanar angles between phenyl groups and the five-membered ring of indenyl vary between 19.4(3) and 44.7(3)°.

Discussion

In light of our previous studies, one would tend to expect that the reactions described here, between the substitutedindenyl complexes [(Ind')Mo(CO)₂(NCMe)₂][BF₄] and spiro[2.4]hepta-4,6-diene, would all end in the corresponding *ansa*-metallocenes as a result of the intramolecular oxidative addition of a C-C bond of the cyclopropyl ring to the Mo(II) ion. Of course, one might expect some rate variations due to the presence of the substituents. In fact, it is usually found that the substitution in the indenvl ring only changes its reactivity slightly, due to the small electronic effects of the substituents.³¹ Surprisingly, though, the experimental data presented above show that the reactions of spiro[2.4]hepta-4,6-diene with methyl-, tert-butyl-, and phenyl-substituted indenyl molybdenum(II) compounds (10-14) are quite sensitive to the presence of substituents on the indenvl ring. The mechanism of these ring-opening reactions in the absence of such substituents has been studied in detail by DFT calculations.¹⁶ It was shown that the $\eta^5 - \eta^3$ haptotropic rearrangement of the indenvl ligand lowers the barrier of the spiro-[2.4]hepta-4,6-diene ring-opening reaction and enables the formation of ansa-compounds. However, this haptotropic shift is not a sufficient condition to enable the C-C bond addition to the Mo(II) metal. In fact, the mechanism entails a number of quite subtle structural rearrangements that are responsible for the lowering of the energetic barriers of several of the steps. Part of this mechanism is depicted in Scheme 7, in accord with the DFT calculations already mentioned.¹⁶ Structure A is the most stable one for the indenyl spiro-diene complexes. However, opening of the cyclopropyl ring from this structure, even after an $\eta^5 \rightarrow \eta^3$ shift of the indenyl ligand, is hampered by very high activation energies. Several other structures are easily accessible from A at room temperature by rotation of the π ligands. Central to this issue is structure **B**, where the OC-Mo-CO group is above the condensed benzene ring of the indenyl ligand and is no longer opposed to it, as in the more stable conformation A. DFT calculations show that it is structure **B** that leads to the lower energy pathway toward ring opening. In the first step the $\eta^5 \rightarrow \eta^3$ haptotropic shift of the indenyl opens the coordination sphere of the Mo(II) ion and allows for the oxidative addition of the C-C bond and formation of the new H_2C -Mo bond, leading to intermediate C. Upon loss of the CO which is trans to the new H₂C-Mo bond the 18e count is restored by the $\eta^3 \rightarrow \eta^5$ indenyl shift. The corresponding structure **D** is only idealized because the whole process following CO loss takes place simultaneously with the structural relaxation toward the metallocene-like structure of the final product E. As depicted in Scheme 8, which is a topdown view of intermediate **B**, the cyclopropyl ring must present itself to the Mo atom from a direction either between the indenyl substituents R^1 and R^2 or between the other substituents R^2 and R^3 .

Both corresponding conformers B1 and B3 are equally accessible and reactive when $R^1 = R^2 = R^3 = H$. However, when bulkier groups are introduced at these positions, differences may arise. When position \mathbb{R}^1 is occupied by a bulky group such as ^tBu, conformer **B1** is disfavored and only one product can be formed: that arising from conformer B3. Following the expulsion of the CO trans to the new H₂C-Mo bond and the rotation of the new Cp' ligand (counterclockwise in this case) to form the E bent-metallocene-like structure, it is clear that the new $Mo-CH_2$ bond will be on the same side as R^1 . This is exactly what is observed in the formation of 15a (Scheme 4). In the case where $R^1 = Ph$, a much less bulky substituent than ^tBu, both conformers **B1** and **B3** can react. However, the product resulting from conformer B3 will obviously be favored over that resulting from the more hindered **B1**. This is experimentally observed and summarized in Scheme 4 and Figure 2. The product resulting from conformer B3 (16a, with the new H₂C-Mo bond on the same side as the Ph substituent) is

^{(23) (}a) Barretta, A.; Cloke, F. G. N.; Feigenbaum, A.; Green,
M. L. H.; Gourdon, A.; Prout, K. J. Chem. Soc., Chem. Commun.
1981, 156–158. (b) Kreiter, C. G.; Wenz, M.; Bell, P. J. Organomet. Chem. 1990, 394, 195–211.

Table 2.	Crystallograph	ic Data of	Molybdenum	Compounds
			•/	

	9	16a	18
formula	C ₂₆ H ₂₀ MoO ₂	C ₂₃ H ₁₉ BF ₄ MoO	C ₂₉ H ₂₃ BF ₄ MoO
formula wt	460.36	494.14	570.22
temp (K)	296(2)	296(2)	150(1)
cryst syst	monoclinic	monoclinic	monoclinic
space group	$P2_1/n$	$P2_1/c$	$P2_1/c$
a (Å)	12.6539(3)	10.6558(4)	9.6430(8)
b (Å)	11.5810(3)	18.9207(8)	11.9781(6)
c (Å)	14.7388(3)	19.6544(8)	22.1769(17)
β (deg)	111.286(1)	92.642 (1)	110.86(1)
$V(Å^3)$	2012.55(8)	3958.4(3)	2393.6(3)
Z	4	8	4
$D_{\rm c} ({\rm g}{\rm cm}^{-3})$	1.519	1.658	1.582
$\mu (\mathrm{mm}^{-1})$	0.671	0.712	0.600
<i>F</i> (000)	936	1984	1152
cryst size (mm)	0.18 imes 0.16 imes 0.06	$0.30 \times 0.18 \times 0.04$	$0.59 \times 0.52 \times 0.30$
θ range (deg)	1.82-30.54	1.49-25.00	1.96-26.6
index ranges	$-18 \le h \le 18$	$-12 \le h \le 10$	$-11 \le h \le 12$
-	$-15 \le k \le 16$	$-22 \le k \le 22$	$-14 \le k \le 15$
	$-21 \le l \le 21$	$-23 \le l \le 23$	$-28 \le l \le 27$
no. of rflns collected	36 519	47 438	15 334
no. of indep rflns	$5223 (R_{int} = 0.0312)$	$6096 (R_{\text{int}} = 0.0292)$	$3474 (R_{int} = 0.0714)$
no. of params	272	536	325
final <i>R</i> indices $(I > 2\sigma(I))^{a,b}$	R1 = 0.0276	R1 = 0.0264	R1 = 0.0565
	wR2 = 0.0657	wR2 = 0.0659	wR2 = 0.1210
final <i>R</i> indices (all data) a,b	R1 = 0.0393	R1 = 0.0305	R1 = 0.0968
	wR2 = 0.0702	wR2 = 0.0754	wR2 = 0.1479
largest diff peak and hole (e $Å^{-3}$)	0.540, -0.712	1.181, -0.481	1.037, -0.922
a R1 = $\sum F_{o} - F_{c} / \sum F_{o} . {}^{b}$ wR2 =	$\sum [w(F_o^2 - F_c^2)^2] / \sum [w(F_o^2)^2])^{1/2}.$		

Scheme 7. Mechanism of the Spiro[2.4]hepta-4,6-diene Ring-Opening Reaction According to Ref 16^{*a*}



^{*a*} Structure **D** is idealized and is only added to help identify the haptotropic shifts accompanying the reaction. The BF_4^- counterion is omitted.

formed in great excess (30:1) over the product resulting from conformer **B1 (16b)**, which would have the Mo–CO bond over the R¹ = ^tBu substituent. When R¹ = R³ = ^tBu, both conformers are hindered and the reaction does not proceed because the C₃ ring is in a position unfavorable to approach the Mo ion (see Scheme 5: **17** is stable). Of course, when R¹ = R³ = Ph the reaction takes place and only one product (**18**) is formed, since there is no energetic difference between **B1** and **B3** (see Scheme 5). We propose that the occupation of the R² position in

Scheme 8. Top-Down View of Intermediate B^a



^{*a*} The spiro-diene is on top with the cyclopropyl ring on a plane perpendicular to the paper projecting from the sp³ carbon. Immediately below the diene plane lies the plane formed by the OC-Mo-CO atoms. The indenyl ring with substituents R^1-R^3 forms the lower, bottom plane. The BF₄⁻ counterion is omitted.

an intermediate such as **B** hinders the approach of the C_3 ring to the Mo and blocks the reaction. This explains the stability of **19** to ring opening and formation of the corresponding *ansa*metallocene. This explanation may be corroborated by DFT calculations using indenyl substituted in the R² position.

The chemistry just described can be readily explained by the previously published computational predictions on the mechanism of C–C activation of spiro-heptadienes coordinated to $[IndMo(CO)_2]^+$ fragments. Interestingly, the stereoselectivity of the reactions performed with substituents on the indenyl ring was shown to be fully compatible with the structural characteristics of the reaction intermediates that are required by the computational results in order to obtain a reaction pathway with feasible activation energies.

Conclusions

The reaction of several ring-substituted Mo(II) cationic complexes of formula $[(Ind')Mo(CO)_2(NCMe)_2][BF_4]$ with spiro[2.4]hepta-4,6-diene led to a number of different outcomes, depending on the nature and position of those substituents. In the cases where the oxidative addition of the C-C bond of the cyclopropyl ring to the Mo(II) central ion

Article

takes place, the reactions occur within the time of mixing and no intermediates could be detected. When the substituent is in the 1-position (Schemes 4 and 8), two diastereoisomers are produced (a and b; see Scheme 4) but the formation of the isomer **a** is highly preferred and becomes exclusive when the bulk of the substituent increases to that of ^tBu. When positions 1 and 3 are occupied simultaneously by bulky ^tBu substituents, the oxidative addition of the cyclopropyl ring is sterically hindered and the very stable η^4 -diene complex 17 (Scheme 5) is obtained. Similar substitution using Ph instead of ^tBu already allows ready oxidative addition and formation of only one compound (18). The presence of one Me group in the 2-position again prevents oxidative addition and leads to the stable η^4 -diene complex 19. This unexpectedly strong reaction discrimination can be easily accommodated by the structural requirements of the C-C oxidative addition reaction that have been previously reported and are elicited by the fluxionality of the cationic $[(Ind')Mo(\eta^4-spiro[2.4]hepta-4,6-diene)(CO)_2]^+$.

Experimental Section

Methods and Materials. All operations were performed under nitrogen using conventional Schlenk-line techniques. The solvents were purified and dried by standard methods.²⁴ Spiro-[2.4]hepta-4,6-diene,¹⁵ 3-*tert*-butylindene,¹⁹ 3-phenylindene,²⁰ 1,3-diphenylindene,²¹ [$(\eta^3$ -C₃H₅)Mo(CO)₂(NCMe)₂CI],¹⁷ [$(\eta^3$ -C₃H₅)Mo(CO)₂(NCMe)₂][B-F₄] (**2**)¹⁸ were prepared according to literature procedures.

Positive-ion electrospray ionization (ESI) mass spectra were recorded on an API-ION TRAP instrument (PO 03 MS). Samples were measured in CH_2Cl_2 solution. The molybdenum-containing ions had a clearly visible metal isotope pattern, arising from the distribution ⁹²Mo 14.84%, ⁹⁴Mo 9.25%, ⁹⁵Mo 15.92%, ⁹⁶Mo 16.68%, ⁹⁷Mo 9.55%, ⁹⁸Mo 24.13%, and ¹⁰⁰Mo 9.63%.²⁶ Spectra obtained were computer-simulated (WSearch32 2005). Mass peaks listed refer to fragments with the isotopes ¹H, ¹¹B, ¹²C, ¹⁴N, ¹⁶O, ¹⁹F, and ⁹⁸Mo. ¹H and ¹³C{¹H} NMR spectra were measured in CDCl₃ solutions on a Bruker Avance 400 spectrometer at room temperature. Chemical shifts are given in ppm relative to TMS. IR spectra were recorded in the 4000–440 cm⁻¹ region (step 2 cm⁻¹) on a Mattson 7000 FT-IR spectrometer using KBr pellets.

Synthesis of 3-*tert*-**Butyl-1**-isopropylideneindene. A solution of 3-*tert*-butylindene (8.61 g, 50 mmol) and acetone (8 mL, 110 mmol) in 100 mL of methanol was treated with crushed KOH pellets (5 g, 90 mmol). The mixture was refluxed overnight, giving an orange oil after workup. Vacuum distillation of the crude product gave a yellow oil (bp 120 °C; 100 Pa). Yield: 8.07 g (38 mmol, 76%). ¹H NMR (CDCl₃; 400 MHz): δ 7.72 (d, ³*J*(¹H, ¹H) = 7.4 Hz, 1H, C₉H₅), 7.56 (d, ³*J*(¹H, ¹H) = 7.5 Hz, 1H, C₉H₅), 7.16 (m, 2H, C₉H₅), 6.52 (s, 1H, C₉H₅), 2.34, 2.21 (2 × s, CH₃), 1.39 (s, 9H, [']Bu). ¹³C NMR (CDCl₃; 101 MHz): δ 150.4, 142.7, 140.1, 137.8, 135.2 (5C_{ipso}), 125.5, 124.2, 123.7, 122.0, 121.5 (5C, C₉H₅), 33.2 (C_{ipso}, [']Bu), 29.8 (3C, [']Bu), 24.9, 23.0 (2C, CH₃).

Synthesis of 1,3-Di-*tert*-butylindene. A solution of 3-*tert*butyl-1-isopropylideneindene (8.07 g, 38 mmol) in THF was treated with methyllithium (60 mmol) and refluxed overnight. The reaction mixture was treated with water and extracted with hexane, giving a yellow oil after workup. Vacuum distillation of the crude product gave a pale yellow oil (bp 100 °C; 100 Pa). Yield: 1.62 g (7 mmol, 18%). ¹H NMR (CDCl₃; 400 MHz): δ 7.55 (m, 2H, C₉H₆), 7.25 (t, ³J(¹H, ¹H) = 7.4 Hz, 1H, C₉H₆), 7.12 (t, ${}^{3}J({}^{1}\text{H}, {}^{1}\text{H}) = 7.5 \text{ Hz}, 1\text{H}, C_{9}H_{6}$), 6.19 (s, 1H, $C_{9}H_{6}$), 3.14 (s, 1H, $C_{9}H_{6}$), 1.37 (s, 9H, ${}^{4}\text{Bu}$), 1.00 (s, 9H, ${}^{4}\text{Bu}$). ${}^{13}\text{C}$ NMR (CDCl₃; 101 MHz): δ 152.7, 148.0, 144.7 (3 C_{ipso}), 130.3, 125.9, 125.2, 123.7, 122.1 (5C, $C_{9}H_{6}$), 58.8 (1C, $C_{9}H_{6}$), 34.5, 33.2 (2 $C_{\text{ipso}}, {}^{7}\text{Bu}$), 29.7, 28.7 (2 × 3C, ${}^{7}\text{Bu}$). Synthesis of $[(\eta^{3}\text{-}C_{3}\text{H}_{5})(\eta^{5}\text{-}C_{9}\text{H}_{6}^{+}\text{Bu})\text{Mo}(\text{CO})_{2}]$ (5). 3-tert-

Butylindene (0.86 g, 5 mmol) was diluted with 30 mL of THF, cooled to 0 °C, and treated dropwise with 3.1 mL of "BuLi $(1.6 \text{ mol } \text{L}^{-1})$. The reaction mixture was stirred overnight and then added dropwise to a THF solution of $[(\eta^3-C_3H_5)Mo(CO)_2-$ (NCMe)₂Cl] (1.55 g, 5 mmol) precooled to -80 °C. The reaction mixture was stirred at room temperature overnight and then vacuum-evaporated to dryness. The solid residue was extracted with hexane at 60 °C. The yellow extract was evaporated to dryness in vacuo. The crude product was recrystallized from hexane at -100 °C and dried in vacuo, giving a yellow powder. Yield: 1.42 g (3.9 mmol, 78%). Anal. Calcd for C₁₈H₂₀MoO₂: C, 59.34; H, 5.53. Found: C, 59.23; H, 5.75. ¹H NMR (CDCl₃; 400 MHz; 4:1 mixture of 5a (exo-C₃H₅) and 5b (endo-C₃H₅)): δ 7.60 (m, 1H, C₉ H_6), 7.35–7.20 (m, 3H, C₉ H_6), 6.13 (d, ³J(¹H, ¹H) = 2.8 Hz, 1H of **a**, C₉H₆), 6.03 (d, ${}^{3}J({}^{1}H, {}^{1}H) = 2.9$ Hz, 1H of **b**, C_9H_6), 5.81 (d, ${}^{3}J({}^{1}H,{}^{1}H) = 2.8$ Hz, 1H of **a**, C_9H_6), 5.77 $(d, {}^{3}J({}^{1}H, {}^{1}H) = 2.9 \text{ Hz}, 1 \text{ H of } \mathbf{b}, C_{9}H_{6}), 3.73 (dd, J({}^{1}H, {}^{1}H) =$ 6.5 Hz, $J({}^{1}H, {}^{1}H) = 2.7$ Hz, 1H of **b**, syn of C₃H₅), 3.65 $(dd, J(^{1}H, ^{1}H) = 6.5 \text{ Hz}, J(^{1}H, ^{1}H) = 2.7 \text{ Hz}, 1H \text{ of } \mathbf{b}, syn \text{ of }$ C_3H_5), 3.54 (m, 1H of **b**, meso of C_3H_5), 2.61 (d, $J({}^{1}H, {}^{1}H) =$ 7.3 Hz, 1H of **a**, syn of C₃H₅), 2.48 (d, $J({}^{1}H, {}^{1}H) = 7.3$ Hz, 1H of **a**, syn of C₃H₅), 1.76 (s, 9H, ^{*t*}Bu), 1.24 (d, $J(^{1}H, ^{1}H) = 11.3$ Hz, 1H of **a**, anti of C₃H₅), 1.11 (d, $J({}^{1}\text{H}, {}^{1}\text{H}) = 11.3$ Hz, 1H of **a**, anti of C_3H_5), 0.01 (m, 1H of **a**, meso of C_3H_5), -0.22 (d, $J(^1H, ^1H) =$ 11.0 Hz, 1H of **b**, *anti* of C₃H₅), -0.89 (d, $J({}^{1}H, {}^{1}H) = 11.0$ Hz, 1H of **b**, anti of C₃H₅). FTIR (KBr, cm⁻¹): 1940 vs (ν_a (CO)), 1860 vs ($\nu_{\rm s}({\rm CO})$).

Synthesis of $[(\eta^3-C_3H_5)(\eta^5-C_9H_6Ph)Mo(CO)_2]$ (6). The reaction was carried out as was described for compound 5, but with 3-phenylindene (0.96 g, 5 mmol). The orange oil of the crude product was used for the next reaction without further purification. Yield: 1.52 g (3.9 mmol, 79%). ¹H NMR (CDCl₃; 400 MHz; 3:1 mixture of **6a** (*exo*-C₃H₅) and **6b** (*endo*-C₃H₅)): δ 7.72–6.95 (m, 5H of C₆H₅ and 4H of C₉H₆), 6.04 (d, ³J(¹H, ¹H) = 2.8 Hz, 1H of **a**, C₉H₆), 6.01 (d, ³J(¹H, ¹H) = 2.8 Hz, 1H of **a**, C₉H₆), 6.01 (d, ³J(¹H, ¹H) = 2.8 Hz, 1H of **a**, C₉H₆), 3.50–3.30 (m, 3H of **b**, C₃H₅), 2.34 (d, J(¹H, ¹H) = 7.2 Hz, 1H of **a**, *syn* of C₃H₅), 0.94 (d, J(¹H, ¹H) = 11.1 Hz, 1H of **a**, *anti* of C₃H₅), 0.84 (d, J(¹H, ¹H) = 11.1 Hz, 1H of **a**, *anti* of C₃H₅), 0.68 (m, 1H of **a**, *meso* of C₃H₅), -0.42 (d, J(¹H, ¹H) = 10.7 Hz, 1H of **b**, *anti* of C₃H₅), -0.72 (d, J(¹H, ¹H) = 10.7 Hz, 1H of **b**, *anti* of C₃H₅), -0.72 (d, J(¹H, ¹H) = 10.7 Hz, 1H of **b**, *anti* of C₃H₅). FTIR (KBr, cm⁻¹): 1940 vs (ν_a (CO)), 1856 vs (ν_s (CO)).

Synthesis of $[(\eta^3 - C_3H_5)(\eta^5 - C_9H_5Ph_2)M_0(CO)_2](8)$. The reaction was carried out as was described for compound 5, but with 1,3-diphenylindene (1.34 g, 5 mmol). The crude product was recrystallized from hexane and dried in vacuo, giving a yellow powder. Yield: 1.54 g (3.3 mmol, 67%). Anal. Calcd for C₂₆H₂₀-MoO₂: C, 67.83; H, 4.38. Found: C, 67.94; H, 4.21. ¹H NMR (CDCl₃; 400 MHz; 3.4:1 mixture of 8a (exo-C₃H₅) and 8b (endo- C_3H_5): δ 7.78–7.05 (m, 10H of C_6H_5 and 4H of C_9H_5), 6.37 (s, 1H of **a**, C_9H_5), 6.35 (s, 1H of **b**, C_9H_5), 3.40 (d, $J({}^{1}H, {}^{1}H) =$ 6.3 Hz, 2H of **b**, syn of C₃H₅), 3.33 (m, 1H of **b**, meso of C₃H₅), 2.17 (d, $J({}^{1}\text{H}, {}^{1}\text{H}) = 7.2 \text{ Hz}, 2\text{H of } \mathbf{a}, syn \text{ of } \text{C}_{3}H_{5}$), 1.11 (m, 1H of **a**, meso of C_3H_5 , 0.88 (d, $J({}^{1}H, {}^{1}H) = 10.9$ Hz, 2H of **a**, anti of C_3H_5), -0.32 (d, $J(^1H, ^1H) = 10.7$ Hz, 2H of **b**, *anti* of C_3H_5). FTIR (KBr, cm⁻¹): 1946 vs (ν_a (CO)), 1854 vs (ν_s (CO)). Crystals suitable for X-ray analysis were obtained upon cooling of the saturated hexane solution from room temperature to -10 °C.

Synthesis of $[(\eta^3-C_3H_5)(\eta^5-C_9H_6Me)Mo(CO)_2]$ (9). The reaction was carried out as was described for compound 5, but with 2-methylindene (0.65 g, 5 mmol). The crude product was recrystallized from Et₂O/hexane at low temperature and dried in vacuo, giving a yellow powder. Yield: 0.95 g (2.9 g, 59%). Anal. Calcd for C₁₅H₁₄MoO₂: C, 55.91; H, 4.38. Found: C, 55.81;

⁽²⁴⁾ Armarego, W. L. F.; Perrin, D. D. In *Purification of Laboratory Chemicals*; Butterworth-Heinemann: Oxford, U.K., 1996.

⁽²⁵⁾ Dieck, H. T.; Friedel, H. J. Organomet. Chem. 1968, 14, 375-385.

⁽²⁶⁾ Vocke, R. D. Pure Appl. Chem. 1999, 71, 1593-1607.

H, 4.56. ¹H NMR (CDCl₃; 400 MHz; 3:1 mixture of **9a** (*exo*-C₃H₅) and **9b** (*endo*-C₃H₅)): δ 7.05–6.85 (m, 4H of C₉H₆), 5.92 (s, 1H of **a**, C₉H₆), 3.43 (d, J(¹H, ¹H) = 6.4 Hz, 2H of **b**, *syn* of C₃H₅), 3.27 (m, 1H of **b**, *meso* of C₃H₅), 2.36 (3H, CH₃), 2.27 (d, J(¹H, ¹H) = 7.3 Hz, 2H of **a**, *syn* of C₃H₅), 0.88 (d, J(¹H, ¹H) = 11.1 Hz, 2H of **a**, *anti* of C₃H₅), 0.19 (m, 1H of **a**, *meso* of C₃H₅), -0.88 (d, J(¹H, ¹H) = 11.0 Hz, 2H of **b**, *anti* of C₃H₅). FTIR (KBr, cm⁻¹): 1945 vs (*v*_a(CO))], 1858 vs (*v*_s(CO)).

Synthesis of $[(\eta^5 - C_9 H_6^t Bu) Mo(CO)_2 (NCMe)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2 (NCME)_2] [BF_4] (10). [(\eta^3 - C_9 H_6^t Bu) Mo(CO)_2] [$ $C_{3}H_{5}(\eta^{5}-C_{9}H_{6}^{t}Bu)Mo(CO)_{2}$] (5; 1.30 g, 3.6 mmol) was dissolved in a CH₂Cl₂/MeCN (1/10) mixture, cooled to 0 °C, and treated with 1 equiv of $HBF_4 \cdot Et_2O$. The solution immediately changed color from yellow to dark red. After 10 min the reaction mixture was warmed to room temperature and stirred for an additional 1 h. The reaction mixture was concentrated in vacuo to \sim 3 mL, and Et₂O was added to precipitate the red powder. The crude product was recrystallized from CH₂Cl₂/hexane, washed with hexane, and dried in vacuo, giving an orange powder. Yield: 1.60 g (3.3 mmol, 91%). Anal. Calcd for C19H21BF4MoN2O2: C, 46.37; H, 4.30; N, 5.69. Found: C, 46.25; H, 4.31; N, 5.88. Positive-ion MS: m/z 366 [M – MeCN]⁺ Negative-ion MS: m/z 87 [BF₄]⁻. ¹H NMR (CDCl₃; 400 MHz): δ 7.80 (d, ${}^{3}J({}^{1}H, {}^{1}H) = 8.6$ Hz, 1H, C₉H₆), 7.63–7.52 (m, 3H, C₉H₆), 5.87 (d, ${}^{3}J({}^{1}H, {}^{1}H) = 2.6$ Hz, 1H, C₉H₆), 4.85(d, 3 $J(^{1}\text{H}, ^{1}\text{H}) = 2.7 \text{ Hz}, 1\text{H}, C_{9}H_{6}), 2.42, 2.41 (2 \times \text{s}, 6\text{H}, CH_{3}\text{CN}),$ 1.42 (s, 9H, ^tBu). ¹³C NMR (CDCl₃; 101 MHz): δ 250.3, 248.6 (2C, CO), 139.6, 138.3 (2C, CH₃CN), 131.9, 130.6, 127.6, 126.7 (4C, C_9H_6), 119.0 (2C_{ipso}, C_9H_6), 113.0 (C_{ipso}, C_9H_6), 87.6, 74.4 (2C, C_9H_6), 33.2 (C_{ipso}, 'Bu), 31.5 (3C, 'Bu), 4.4, 4.2 (2C, CH_3CN). FTIR (KBr, cm⁻¹): 2287 m ($\nu_a(CN)$), 2252 m (v_s(CN)), 1959 vs (v_a(CO)), 1865 vs (v_s(CO)), 1055 vs-br $(\nu_{s}(BF)).$

Synthesis of $[(\eta^5 - C_9 H_6 Ph) Mo(CO)_2 (NCMe)_2] [BF_4]$ (11). The reaction was carried out as was described for compound 10, but with $[(\eta^3 - C_3H_5)(\eta^5 - C_9H_6Ph)Mo(CO)_2]$ (6; 1.40 g, 3.6 mmol). The crude product was recrystallized from CH₂Cl₂/hexane, washed with hexane, and dried in vacuo, giving an orange powder. Yield: 1.62 g (3.2 mmol, 87%). Anal. Calcd for C₂₁H₁₇BF₄MoN₂O₂: C, 49.25; H, 3.35; N, 5.47. Found: C, 49.34; H, 3.58; N, 5.22. Positive-ion MS: m/z 386 [M - MeCN]⁺. Negative-ion MS: m/z 87 [BF₄]⁻. ¹H NMR (CDCl₃; 400 MHz): δ 7.87 (d, ³*J*(¹H, ¹H) = 8.4 Hz, 1H, C₉*H*₆), 7.67–7.37 (m, 3H of C_9H_6 and 5H of C_6H_5), 6.04 (d, ${}^{3}J({}^{1}H, {}^{1}H) = 2.6$ Hz, 1H, C_9H_6), 5.37 (d, ${}^{3}J({}^{1}H,{}^{1}H) = 2.7$ Hz, 1H, C₉H₆), 2.47, 2.46 (2 × s, 6H, CH₃CN). ${}^{13}C$ NMR (CDCl₃; 101 MHz): δ 248.1, 247.0 (2C, CO), 140.2, 139.4 (2C, CH₃CN), 132.9 (C_{ipso} , C_6H_5), 131.9, 131.4 (2C, C_9H_6), 129.4 (2C, C_6H_5), 129.3 (1C, C_6H_5), 128.6 (2C, C₆H₅), 127.1, 125.5 (2C, C₉H₆), 117.7 (2C_{ipso}, C₉H₆), 101.5 (C_{ipso}, C₉H₆), 88.8, 76.3 (2C, C₉H₆), 4.6, 4.5 (2C, CH₃CN). FTIR (KBr, cm⁻¹): 2310 m (ν_a (CN)), 2279 m (ν_s (CN)), 1962 vs $(\nu_{a}(CO))$, 1874 vs $(\nu_{s}(CO))$, 1060 vs-br $(\nu_{s}(BF))$.

Synthesis of $[(\eta^5 - C_9 H_5^t Bu_2) Mo(CO)_2 (NCMe)_2] [BF_4]$ (12). 1,3-Di-tert-butylindene (1.14 g, 5 mmol) was diluted with 30 mL of THF, cooled to 0 °C, and treated dropwise with 3.1 mL of "BuLi $(1.6 \text{ mol } \text{L}^{-1})$. The reaction mixture was stirred overnight and then added dropwise to a THF solution of $[(\eta^3-C_3H_5)Mo(CO)_2 (NCMe)_2Cl]$ (1.55 g, 5 mmol) precooled to -80 °C. The reaction mixture was stirred at room temperature overnight and then vacuum-evaporated to dryness. The solid residue was extracted with hexane at 60 °C. The yellow extract was evaporated to dryness in vacuo, recrystallized from Et₂O/hexane at -60 °C, and dried in vacuo, giving a yellow powder. The crude $[(\eta^3-C_3H_5)(\eta^5-C_9H_5-$ ^tBu₂)Mo(CO)₂] (7; 1.5 g, 3.5 mmol) was dissolved in a CH₂Cl₂/ MeCN (1/10) mixture, cooled to 0 °C, and treated with 1 equiv of HBF₄·Et₂O. The solution immediately changed color from yellow to dark red. After 10 min the reaction mixture was warmed to room temperature and stirred for an additional 1 h. The reaction mixture was concentrated in vacuo to ~3 mL, and Et₂O was added to precipitate the red powder. The crude product was recrystallized from CH₂Cl₂/hexane, washed with hexane, and dried in vacuo,

giving an orange powder. Yield: 1.47 g (2.7 mmol, 54%). Anal. Calcd for $C_{23}H_{29}BF_4MoN_2O_2$: C, 50.39; H, 5.33; N, 5.11. Found: C, 50.24; H, 5.21; N, 5.39. Positive-ion MS: m/z 422 [M – MeCN]⁺. Negative-ion MS: m/z 87 [BF₄]⁻. ¹H NMR (CDCl₃; 400 MHz): δ 7.80 (m, 2H, C_9H_5), 7.58 (m, 2H, C_9H_5), 4.75 (s, 1H, C_9H_5), 2.41 (s, 6H, CH_3CN), 2.41 (s, 18H, ¹Bu). ¹³C NMR (CDCl₃; 101 MHz): δ 252.1 (2C, CO), 138.8 (2C, CH₃CN), 130.8, 127.7 (2C, C_9H_5), 118.9 (2C_{ipso}, C_9H_5), 110.4 (2C_{ipso}, C_9H_5), 87.1 (1C, C_9H_5), 33.1 (2C_{ipso}, ¹Bu), 31.6 (6C, ¹Bu), 4.3 (2C, CH_3CN). FTIR (KBr, cm⁻¹): 2315 m [ν_a (CN)], 2289 m [ν_s (CN)], 1960 vs [ν_a (CO)], 1882 vs [ν_s (CO)], 1056 vs-br [ν_s (BF)].

Synthesis of $[(\eta^5-C_9H_5Ph_2)Mo(CO)_2(NCMe)_2][BF_4]$ (13). The reaction was carried out as was described for compound 10, but with $[(\eta^3-C_3H_5)(\eta^5-C_9H_5Ph_2)Mo(CO)_2]$ (8; 1.45 g, 3.1 mmol). The crude product was recrystallized from CH₂Cl₂/hexane, washed with hexane, and dried in vacuo, giving an orange powder. Yield: 1.63 g (2.8 mmol, 88%). Anal. Calcd for C₂₇H₂₁BF₄Mo-N₂O₂: C, 55.13; H, 3.60; N, 4.76. Found: C, 54.96; H, 3.23; N, 4.57. Positive-ion MS: *m*/*z* 462 [M – MeCN]⁺. Negative-ion MS: *m*/*z* 87 [BF₄]⁻. ¹H NMR (CDCl₃; 400 MHz): δ 7.89 (m, 2H, C₉H₅), 7.63 (d, *J*(¹H, ¹H) = 7.4 Hz, 4H, C₆H₅), 7.52–7.40 (m, 6H, C₆H₅), 5.75 (s, 1H, C₉H₅), 2.51 (s, 6H, CH₃CN). FTIR (KBr, cm⁻¹): 2319 m (ν_a (CN)), 2286 m (ν_s (CN)), 1972 vs (ν_a (CO)), 1903 vs (ν_s (CO)), 1056 vs-br (ν_s (BF)).

Synthesis of $[(\eta^5-C_9H_6Me)Mo(CO)_2(NCMe)_2][BF_4]$ (14). The reaction was carried out as was described for compound 10, but with $[(\eta^3-C_3H_5)(\eta^5-C_9H_6Me)Mo(CO)_2]$ (9; 0.80 g, 2.5 mmol). The crude product was recrystallized from CH₂Cl₂/hexane, washed with hexane, and dried in vacuo, giving an orange powder. Yield: 1.02 g (2.3 mmol, 91%). Anal. Calcd for C₁₆H₁₅BF₄Mo-N₂O₂: C, 42.70; H, 3.36; N, 6.22. Found: C, 42.51; H, 3.14; N, 6.01. Positive-ion MS: m/z 324 [M – MeCN]⁺. Negative-ion MS: m/z 87 [BF₄]⁻. ¹H NMR (CDCl₃; 400 MHz): δ 7.51 (m, 4H, C₉H₆), 5.90 (s, 2H, C₉H₆), 2.43 (s, 6H, CH₃CN), 1.88 (s, 3H, CH₃). ¹³C NMR (CDCl₃; 101 MHz): δ 249.7 (2C, CO), 139.9 (2C, CH₃CN), 131.3 (2C, C₉H₆), 126.2 (2C, C₉H₆), 118.4 (2C_{ipso}, C₉H₆), 78.6 (2C, C₉H₆), 110.4 (2C_{ipso}, C₉H₆), 108.7 (1C_{ipso}, C₉H₆), 15.5 (1C, CH₃), 4.5 (2C, CH₃CN). FTIR (KBr, cm⁻¹): 2293 m (ν_a (CN)), 2253 m (ν_s (CN)), 1948 vs (ν_a (CO)), 1875 vs (ν_s (CO)), 1060 vs-br (ν_s (BF)).

Synthesis of $[(\eta^5 - C_9 H_6^t Bu)(\eta^5 - C_5 H_4 CH_2 - \eta^1 - CH_2)Mo(CO)]$ -[BF₄] (15). A solution of $[(\eta^5 - C_9 H_6^t Bu)Mo(CO)_2(NCMe)_2][BF_4]$ (10; 0.20 g, 0.4 mmol) in CH_2Cl_2 (20 mL) was treated with an excess of spiro[2.4]hepta-4,6-diene (0.1 g, 1.1 mmol). After it was stirred for 15 min, the reaction mixture was concentrated in vacuo to ca. 3 mL. Addition of Et₂O precipitated an orange powder that was recrystallized from CH₂Cl₂/Et₂O. Yield: 0.18 g (0.38 mmol, 93%). Anal. Calcd for C₂₁H₂₃BF₄MoO: C, 53.19; H, 4.89. Found: C, 53.36; H, 4.73. Positive-ion MS: m/z 389 $[M]^+$. Negative-ion MS: m/z 87 $[BF_4]^-$. ¹H NMR (CDCl₃; 400 MHz): δ 7.67 (d, ${}^{3}J({}^{1}H, {}^{1}H) = 8.5$ Hz, 1H, C₉H₆), 7.50-7.42 (m, 2H, C₉ H_6), 7.32 (m, 1H, C₉ H_6), 6.50 (m, 1H, C₅ H_4), 6.38 (d, ${}^{3}J({}^{1}\text{H},{}^{1}\text{H}) = 3.5$ Hz, 1H, C₉ H_6), 5.63 (d, ${}^{3}J({}^{1}\text{H},{}^{1}\text{H}) =$ 3.5 Hz, 1H, C₉ H_6), 5.56, 4.90, 4.73 (3 × m, 3H, C₅ H_4), 2.54 (m, 6 lines, 1H, CH₂CH₂Mo), 2.31 (m, 6 lines, 1H, CH₂CH₂-Mo), 1.44 (s, 9H, ^tBu), -0.70 (m, 5 lines, 1H, CH₂CH₂Mo), -3.05 (m, 7 lines, 1H, CH₂CH₂Mo). ¹³C NMR (CDCl₃; 101 MHz): δ 228.5 (1C, CO), 131.6, 130.0, 127.5, 124.3 (4C, C_9H_6), 117.2, 112.5, 110.5 ($3C_{ipso}$, C_9H_6), 97.1, 92.7, 90.1 (3C, C_5H_4), 84.9 (1C, C_9H_6), 81.6 (1C, C_5H_4), 81.4 (1C, C_9H_6), 80.6 (C_{ipso} , C_5H_4), 33.8 (C_{ipso} , [']Bu), 31.5 (3C, [']Bu), 18.6 (1C, CH_2 -CH₂Mo), -38.5 (1C, CH₂CH₂Mo). FTIR (KBr, cm⁻¹): 1999 vs $(\nu(CO)), 1056 \text{ vs-br} (\nu_s(BF)).$

Synthesis of $[(\eta^5-C_9H_6Ph)(\eta^5-C_5H_4CH_2-\eta^1-CH_2)M_0(CO)]$ -[BF₄] (16). The reaction was carried out as was described for compound 15, but with $[(\eta^5-C_9H_6Ph)M_0(CO)_2(NCMe)_2][BF_4]$ (11; 0.20 g, 0.4 mmol). The product recrystallized from CH₂Cl₂/ Et₂O contains a 30:1 mixture of 16a and 16b. Repeated recrystallization from a CH₂Cl₂/hexane mixture gives a pure sample of 16a. Yield: 0.17 g (0.34 mmol, 88%). Anal. Calcd for C₂₃H₁₉-BF₄MoO: C, 55.90; H, 3.88. Found: C, 55.61; H, 3.72. Positive-ion

MS: m/z 409 [M]⁺. Negative-ion MS: m/z 87 [BF₄]⁻. ¹H NMR (CDCl₃; 400 MHz) of **16a**: δ 7.93 (d, ³*J*(¹H, ¹H) = 8.8 Hz, 1H, C₉H₆), 7.62 (m, 1H, C₉H₆), 7.56-7.39 (m, 2H of C₉H₆, and 5H of C₆H₅), 6.77 (m, 1H, C₅H₄), 6.65 (d, ${}^{3}J({}^{1}H, {}^{1}H) = 3.5$ Hz, 1H, C₉H₆), 6.02 (d, ${}^{3}J({}^{1}H, {}^{1}H) = 3.5$ Hz, 1H, C₉H₆), 5.67, $4.73, 4.58 (3 \times m, 3H, C_5H_4), 2.46 (m, 6 lines, 1H, CH_2CH_2M_0),$ 2.36 (m, 6 lines, 1H, CH2CH2Mo), -0.09 (m, 5 lines, 1H, CH2- CH_2Mo), -3.75 (m, 7 lines, 1H, CH_2CH_2Mo). ¹³C NMR (CDCl₃; 101 MHz) of 16a: \delta 226.5 (1C, CO), 133.1, 130.7, 130.3, 128.1 (3C of C_9H_6 and 1C of C_6H_5), 131.1 (C_{ipso} , C_6H_5), 129.7, 128.3 (2 × 2C, C_6H_5), 122.5 (1C, C_9H_6), 114.4, 106.4, 105.7 (3C_{ipso}, C₉H₆), 98.1, 95.6, 89.8 (3C, C₅H₄), 83.2 (1C, C_9H_6), 82.7 (1C, C_5H_4), 82.1 (1C, C_9H_6), 81.3 (C_{ipso} , C_5H_4), 18.7 (1C, CH₂CH₂Mo), -36.0 (1C, CH₂CH₂Mo). FTIR (KBr, cm⁻¹): 2002 vs (ν (CO))], 1059 vs-br (ν_s (BF)). ¹H NMR (CDCl₃; 400 MHz) of **16b** (selected signals): δ -0.49 (m, 5 lines, 1H, CH_2CH_2Mo), -1.63 (m, 5 lines, 1H, CH_2CH_2Mo). Single crystals of 16a suitable for X-ray analysis were prepared by slow evaporation of the CDCl₃ solution.

Synthesis of $[(\eta^5 - C_9H_5^tBu_2)(\eta^4 - C_5H_4(CH_2)_2)Mo(CO)_2][BF_4]$ (17). The reaction was carried out as was described for compound 15, but with $[(\eta^5-C_9H_5^tBu_2)Mo(CO)_2(NCMe)_2][BF_4]$ (12; 0.22 g, 0.4 mmol). Yield: 0.14 g (0.24 mmol, 59%). Anal. Calcd for C₂₆H₃₁BF₄MoO₂: C, 55.94; H, 5.60. Found: C, 56.29; H, 5.83. ¹H NMR (CDCl₃; 400 MHz): 7.79 (m, 2H, C₉H₅), 7.63 (m, 2H, C₉H₅), 5.54 (t, $J(^{1}H, ^{1}H) = 2.9$ Hz, 2H, C₅H₄), 5.20 (s, 1H, C₉H₅), 4.19 (t, $J(^{1}H, ^{1}H) = 2.9$ Hz, 2H, C₅H₄), 2.42 (s, 18H, 'Bu), 1.36 (t, $^{3}J(^{1}H, ^{1}H) = 8.6$ Hz, 2H, CH₂), 0.67 (t, ${}^{3}J({}^{1}H,{}^{1}H) = 8.6$ Hz, 2H, CH₂).

Synthesis of $[(\eta^5 - C_9H_5Ph_2)(\eta^5 - C_5H_4CH_2 - \eta^1 - CH_2)M_0(CO)]$ -[BF₄] (18). The reaction was carried out as was described for compound 15, but with $[(\eta^5-C_9H_5Ph_2)Mo(CO)_2(NCMe)_2][BF_4]$ (13; 0.24 g, 0.4 mmol). Yield: 0.22 g (0.39 mmol, 94%). Anal. Calcd for C₂₉H₂₃BF₄MoO: C, 61.08; H, 4.07. Found: C, 60.86; H, 3.92. Positive-ion MS: m/z 485 [M]⁺. Negative-ion MS: m/z87 [BF₄]⁻. ¹H NMR (CDCl₃; 400 MHz): δ 8.02 (m, 1H, C₉H₅), 7.71 (m, 1H, C₉H₅), 7.62 (m, 6H, C₉H₅ and C₆H₅), 7.53 (m, 4H, C₆H₅), 7.41 (m, 2H, C₆H₅), 6.39 (s, 1H, C₉H₅), 5.53 (m, 1H, C₅H₄), 4.74 (m, 2H, C₅H₄), 4.40 (m, 1H, C₅H₄), 2.62 (m, 6 lines, 1H, CH₂CH₂Mo), 2.34 (m, 8 lines, 1H, CH₂CH₂Mo), -0.32 (m, 6 lines, 1H, CH₂CH₂Mo), -2.50 (m, 7 lines, 1H, CH₂-CH₂Mo). ¹³C NMR (CDCl₃; 101 MHz): δ 225.3 (1C, CO), 131.8, 131.6, 130.4, 130.3 (2C of C₆H₅ and 2C of C₉H₅), 131.4, 130.9 (2 C_{ipso} , C_6H_5), 130.2, 129.9, 128.2, 127.8 (4 × 2C, C_6H_5), 124.8, 12 $\hat{4}.6$ (2C, C_9H_5), 110.6, 106.7, 103.6, 102.8 (4C_{ipso}, C₉H₅), 105.4, 97.3, 90.3, 85.9, 84.4 (4C of C₅H₄ and 1C of C_9H_5), 80.0 (C_{ipso} , C_5H_4), 18.8 (1C, CH_2CH_2Mo), -36.7 (1C, CH_2CH_2Mo). FTIR (KBr, cm⁻¹): 2006 vs (ν (CO)), 1054 vs-br $(\nu_{s}(BF))$. Single crystals suitable for X-ray analysis were prepared by careful overlayering of the CH₂Cl₂ solution with hexane.

Synthesis of $[(\eta^5-C_9H_6Me)(\eta^4-C_5H_4(CH_2)_2)Mo(CO)_2][BF_4]$ (19). The reaction was carried out as was described for compound 15, but with $[(\eta^{2}-C_{9}H_{6}Me)Mo(CO)_{2}(NCMe)_{2}][BF_{4}]$ (14; 0.18 g, 0.4 mmol). Yield: 0.10 g (0.22 mmol, 54%). Anal. Calcd for C₁₉H₁₇BF₄MoO₂: C, 49.60; H, 3.72. Found: C, 49.88; H, 4.03. ¹H NMR (CDCl₃; 400 MHz): 7.67 (m, 2H, C₉H₆), 7.38 (m, 2H, C₉H₆), 6.20 (s, 2H, C₉H₆), 5.28 (t, $J({}^{1}H, {}^{1}H) = 2.9$ Hz, 2H, C_5H_4 , 4.70 (t, $J({}^{1}H, {}^{1}H) = 2.9$ Hz, 2H, C_5H_4), 2.26 (s, 3H, CH₃), $1.16(t, {}^{3}J({}^{1}H, {}^{1}H) = 8.4 \text{ Hz}, 2H, CH_{2}), 0.52(t, {}^{3}J({}^{1}H, {}^{1}H) = 8.4$ Hz, 2H, CH₂).

X-ray Structure Determination. The measurements of structures 9 and 16a were carried out on a Bruker SMART APEX CCD diffractometer using graphite-monochromated Mo Ka radiation ($\lambda = 0.71073$ Å) from an X-ray tube. Details of the crystallographic data and refinement parameters are given in Table 2. Programs used: data collection, Smart (Bruker 2003); data reduction, Saint (Bruker version 6); absorption correction, SADABS version 2.10 (Bruker AXS 2001). Structure solution and refinement was done using SHELXTL (Bruker 2003). The structure was solved by direct methods and refined by fullmatrix least-squares methods on F^2 . The non-hydrogen atoms were refined anisotropically. There is a disordered carbon atom of the C-H fragment originating from the allyl moiety. This disorder was solved by standard constraint and restraint procedures in the SHELXL97 software.27 The allyl ligand of compound 8 has positional disorder. It was refined in *exo* and *endo* orientations with 60% and 40% occupancy, respectively. The hydrogen atoms of the η^3 -allyl were refined only for the major isomer

The X-ray data (Table 2) for crystals of 18 were obtained at 150 K using an Oxford Cryostream low-temperature device on a Nonius KappaCCD diffractometer with Mo K α radiation ($\lambda =$ 0.71073 Å) and a graphite monochromator. Data reductions were performed with DENZO-SMN.²⁸ The absorption was corrected by integration methods.²⁹ Structures were solved by direct methods (Sir92)³⁰ and refined by full-matrix least squares based on F^2 (SHELXL97).²⁷ Hydrogen atoms were mostly localized on a difference Fourier map; however, to ensure uniformity of the treatment of the crystal, all hydrogen atoms were recalculated into idealized positions (riding model) and assigned temperature factors $U_{iso}(H) = 1.2[U_{eq}(\text{pivot atom})] \text{ or}$ $1.5U_{eq}$ for the methyl moiety with C-H = 0.96, 0.97, and 0.93 Å for methyl, methylene, and hydrogen atoms in aromatic rings or the allyl moiety, respectively.

Crystallographic data for structural analysis have been deposited with the Cambridge Crystallographic Data Centre. Copies of this information may be obtained free of charge from The Director, CCDC, 12 Union Road, Cambridge CB2 1EY, U.K. (fax, +44-1223-336033; e-mail, deposit@ccdc.cam.ac.uk; web, http://www.ccdc.cam.ac.uk).

Acknowledgment. We are grateful to the Czech Science Foundation (GACR, Czech Republic) and Ministry of Education of the Czech Republic (MSM, Czech Republic) for support through projects GACR/203/09/P100 and MSM 0021627501, respectively. J.H. thanks the FCT for the postdoctoral research grant SFRH/BPD/24889/2005. A.M. thanks the FCT for the postdoctoral research grant SFRH/BPD/30142/2006. We thank Cecilia Bonifácio from the FCT-UNL and Paula Brandão from the Universidade de Aveiro for crystal mounting and data collection. We thank the FCT (Portugal) for the funding of the singlecrystal diffractometer. The NMR spectrometers are part of the National NMR Network and were acquired with funds from the FCT and FEDER.

Supporting Information Available: CIF files giving crystallographic data for 9, 16a, and 18. This material is available free of charge via the Internet at http://pubs.acs.org.

⁽²⁷⁾ Sheldrick, G. M. SHELXL97; University of Göttingen, Göttingen, Germany, 1997

⁽²⁸⁾ Otwinowski, Z.; Minor, W. Methods Enzymol. 1997, 276, 307-32è.

⁽²⁹⁾ Coppens, P. In *Crystallographic Computing*; Munksgaard: Copenhagen, 1970; pp 255–270.

⁽³⁰⁾ Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A. J. Appl. Crystallogr. 1993, 26, 343-350.

^{(31) (}a) King, R. B.; Bisnette, M. B. Inorg. Chem. 1965, 4, 475–481.
(b) Green, M.; McGrath, T. D.; Thomas, R. L.; Walker, A. P. J. Organomet. Chem. 1997, 532, 61–70.